Structure Therapeutics Inc. (NASDAQ:GPCR) Receives $81.29 Consensus Price Target from Analysts

Structure Therapeutics Inc. (NASDAQ:GPCR) has been assigned a consensus recommendation of “Buy” from the eight brokerages that are presently covering the stock, MarketBeat reports. Eight research analysts have rated the stock with a buy rating. The average 12-month price target among analysts that have issued a report on the stock in the last year is $81.29.

A number of equities research analysts recently issued reports on GPCR shares. Stifel Nicolaus assumed coverage on shares of Structure Therapeutics in a report on Wednesday, January 8th. They issued a “buy” rating and a $50.00 price objective for the company. JMP Securities reissued a “market outperform” rating and issued a $91.00 price target on shares of Structure Therapeutics in a research note on Wednesday, December 18th. HC Wainwright reaffirmed a “buy” rating and set a $80.00 price target on shares of Structure Therapeutics in a research report on Thursday, December 19th. Finally, William Blair assumed coverage on Structure Therapeutics in a research report on Friday, February 28th. They issued an “outperform” rating for the company.

Institutional Investors Weigh In On Structure Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Wellington Management Group LLP boosted its holdings in Structure Therapeutics by 2.9% during the 3rd quarter. Wellington Management Group LLP now owns 7,769,771 shares of the company’s stock valued at $341,015,000 after acquiring an additional 221,851 shares during the period. FMR LLC boosted its stake in shares of Structure Therapeutics by 6.7% in the third quarter. FMR LLC now owns 6,128,444 shares of the company’s stock valued at $268,977,000 after purchasing an additional 383,635 shares during the period. Janus Henderson Group PLC grew its holdings in shares of Structure Therapeutics by 5.1% in the fourth quarter. Janus Henderson Group PLC now owns 4,159,888 shares of the company’s stock valued at $112,816,000 after purchasing an additional 203,010 shares in the last quarter. Deep Track Capital LP increased its stake in Structure Therapeutics by 129.4% during the 4th quarter. Deep Track Capital LP now owns 2,800,000 shares of the company’s stock worth $75,936,000 after buying an additional 1,579,492 shares during the period. Finally, Vestal Point Capital LP lifted its holdings in Structure Therapeutics by 50.0% during the 4th quarter. Vestal Point Capital LP now owns 1,725,000 shares of the company’s stock worth $46,782,000 after buying an additional 575,000 shares in the last quarter. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Price Performance

Shares of Structure Therapeutics stock opened at $19.77 on Tuesday. The stock’s 50 day simple moving average is $24.19 and its 200-day simple moving average is $31.22. The stock has a market cap of $1.13 billion, a P/E ratio of -26.72 and a beta of -2.37. Structure Therapeutics has a 1-year low of $18.87 and a 1-year high of $62.74.

Structure Therapeutics (NASDAQ:GPCR) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.01. As a group, research analysts expect that Structure Therapeutics will post -0.82 EPS for the current fiscal year.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.